Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL.

Clin Vaccine Immunol. 2015 Mar;22(3):298-303. doi: 10.1128/CVI.00618-14. Epub 2014 Dec 31.

2.

Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.

Zhan X, Slobod KS, Jones BG, Sealy RE, Takimoto T, Boyd K, Surman S, Russell CJ, Portner A, Hurwitz JL.

Int Immunol. 2015 May;27(5):229-36. doi: 10.1093/intimm/dxu107. Epub 2014 Dec 4.

3.

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, Dormitzer PR, DeVincenzo J, Hurwitz JL.

Vaccine. 2014 May 30;32(26):3264-73. doi: 10.1016/j.vaccine.2014.03.088. Epub 2014 Apr 14.

4.

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL.

Vaccine. 2012 Jan 20;30(5):959-68. doi: 10.1016/j.vaccine.2011.11.046. Epub 2011 Nov 23. Erratum in: Vaccine. 2012 Nov 6;30(48):6955. Dosage error in article text.

5.

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.

Alymova IV, Portner A, Mishin VP, McCullers JA, Freiden P, Taylor GL.

Glycobiology. 2012 Feb;22(2):174-80. doi: 10.1093/glycob/cwr112. Epub 2011 Aug 16.

6.

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.

Mishin VP, Watanabe M, Taylor G, Devincenzo J, Bose M, Portner A, Alymova IV.

J Virol. 2010 Mar;84(6):3094-100. doi: 10.1128/JVI.02331-09. Epub 2010 Jan 6.

7.

Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation.

Alymova IV, Watanabe M, Boyd KL, Chand P, Babu YS, Portner A.

Antivir Ther. 2009;14(7):891-8. doi: 10.3851/IMP1420.

8.

Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice.

Luque LE, Bridges OA, Mason JN, Boyd KL, Portner A, Russell CJ.

J Virol. 2010 Jan;84(2):810-21. doi: 10.1128/JVI.01990-09. Epub 2009 Nov 11.

9.

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Watanabe M, Mishin VP, Brown SA, Russell CJ, Boyd K, Babu YS, Taylor G, Xiong X, Yan X, Portner A, Alymova IV.

Antimicrob Agents Chemother. 2009 Sep;53(9):3942-51. doi: 10.1128/AAC.00220-09. Epub 2009 Jun 29.

10.

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL.

Vaccine. 2009 Mar 13;27(12):1848-57. doi: 10.1016/j.vaccine.2009.01.041. Epub 2009 Feb 4.

11.

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Alymova IV, Taylor G, Mishin VP, Watanabe M, Murti KG, Boyd K, Chand P, Babu YS, Portner A.

J Virol. 2008 Sep;82(17):8400-10. doi: 10.1128/JVI.00474-08. Epub 2008 Jun 25.

12.

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, Surman S, Russell CJ, Portner A, Hurwitz JL.

Vaccine. 2008 Jun 25;26(27-28):3480-8. doi: 10.1016/j.vaccine.2008.04.022. Epub 2008 May 1.

13.

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B.

Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, Surman S, Portner A, Slobod KS.

Vaccine. 2007 Dec 17;25(52):8782-93. Epub 2007 Nov 5.

14.

Nontypeable Haemophilus influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein.

Avadhanula V, Wang Y, Portner A, Adderson E.

J Med Microbiol. 2007 Sep;56(Pt 9):1133-7.

PMID:
17761473
15.

A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein.

Brown SA, Hurwitz JL, Zirkel A, Surman S, Takimoto T, Alymova I, Coleclough C, Portner A, Doherty PC, Slobod KS.

J Virol. 2007 Nov;81(22):12535-42. Epub 2007 Jul 25.

16.
17.

Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment.

Bousse T, Chambers RL, Scroggs RA, Portner A, Takimoto T.

Virus Res. 2006 Oct;121(1):23-32. Epub 2006 May 3.

PMID:
16677733
18.

Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus.

Ryan C, Zaitsev V, Tindal DJ, Dyason JC, Thomson RJ, Alymova I, Portner A, von Itzstein M, Taylor G.

Glycoconj J. 2006 Feb;23(1-2):135-41.

PMID:
16575531
19.

Neuraminidase inhibitors as antiviral agents.

Alymova IV, Taylor G, Portner A.

Curr Drug Targets Infect Disord. 2005 Dec;5(4):401-9. Review.

PMID:
16535861
20.

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.

Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd K, Scroggs RA, Portner A, Slobod KS.

Viral Immunol. 2005;18(2):255-66. Review.

PMID:
16035938
21.

The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.

Alymova IV, Portner A, Takimoto T, Boyd KL, Babu YS, McCullers JA.

Antimicrob Agents Chemother. 2005 Jan;49(1):398-405.

22.

Molecular mechanism of paramyxovirus budding.

Takimoto T, Portner A.

Virus Res. 2004 Dec;106(2):133-45. Review.

PMID:
15567493
23.

Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein.

Bousse TL, Taylor G, Krishnamurthy S, Portner A, Samal SK, Takimoto T.

J Virol. 2004 Dec;78(23):13351-5.

24.

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.

Slobod KS, Shenep JL, Luján-Zilbermann J, Allison K, Brown B, Scroggs RA, Portner A, Coleclough C, Hurwitz JL.

Vaccine. 2004 Aug 13;22(23-24):3182-6.

PMID:
15297072
25.

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS.

J Virol. 2004 Jun;78(11):6043-7.

26.

Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Alymova IV, Taylor G, Takimoto T, Lin TH, Chand P, Babu YS, Li C, Xiong X, Portner A.

Antimicrob Agents Chemother. 2004 May;48(5):1495-502.

27.

Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion.

Zaitsev V, von Itzstein M, Groves D, Kiefel M, Takimoto T, Portner A, Taylor G.

J Virol. 2004 Apr;78(7):3733-41.

28.

Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion.

Takimoto T, Taylor GL, Connaris HC, Crennell SJ, Portner A.

J Virol. 2002 Dec;76(24):13028-33.

29.
30.
31.

Role of matrix and fusion proteins in budding of Sendai virus.

Takimoto T, Murti KG, Bousse T, Scroggs RA, Portner A.

J Virol. 2001 Dec;75(23):11384-91.

32.
33.

Receptor specificities of human respiroviruses.

Suzuki T, Portner A, Scroggs RA, Uchikawa M, Koyama N, Matsuo K, Suzuki Y, Takimoto T.

J Virol. 2001 May;75(10):4604-13.

34.

Nucleocapsid incorporation into parainfluenza virus is regulated by specific interaction with matrix protein.

Coronel EC, Takimoto T, Murti KG, Varich N, Portner A.

J Virol. 2001 Feb;75(3):1117-23.

35.

Molecular cloning and expression of human parainfluenza virus type 1 L gene.

Takimoto T, Bousse T, Portner A.

Virus Res. 2000 Sep;70(1-2):45-53.

PMID:
11074124
36.

Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase.

Crennell S, Takimoto T, Portner A, Taylor G.

Nat Struct Biol. 2000 Nov;7(11):1068-74.

PMID:
11062565
37.

Crystallization of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.

Takimoto T, Taylor GL, Crennell SJ, Scroggs RA, Portner A.

Virology. 2000 Apr 25;270(1):208-14.

39.

Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions.

Takimoto T, Bousse T, Coronel EC, Scroggs RA, Portner A.

J Virol. 1998 Dec;72(12):9747-54.

40.

The M2 ectodomain is important for its incorporation into influenza A virions.

Park EK, Castrucci MR, Portner A, Kawaoka Y.

J Virol. 1998 Mar;72(3):2449-55.

41.

Elevated expression of the human parainfluenza virus type 1 F gene downregulates HN expression.

Bousse T, Takimoto T, Murti KG, Portner A.

Virology. 1997 May 26;232(1):44-52.

42.

Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one.

Hurwitz JL, Soike KF, Sangster MY, Portner A, Sealy RE, Dawson DH, Coleclough C.

Vaccine. 1997 Apr;15(5):533-40.

PMID:
9160521
43.

Inter- and intra-patient sequence diversity among parainfluenza virus-type 1 nucleoprotein genes.

Dave VP, Hetherington SV, Portner A, Leggiadro RJ, Hurwitz JL.

Virus Genes. 1997;14(2):153-6.

PMID:
9237355
44.
46.

Molecular evolution of the F glycoprotein of human parainfluenza virus type 1.

Ambrose MR, Hetherington SV, Watson AS, Scroggs RA, Portner A.

J Infect Dis. 1995 Apr;171(4):851-6.

PMID:
7706810
47.

Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1.

Smith FS, Portner A, Leggiadro RJ, Turner EV, Hurwitz JL.

Virology. 1994 Dec;205(2):453-61.

PMID:
7975247
48.

Regions on the hemagglutinin-neuraminidase proteins of human parainfluenza virus type-1 and Sendai virus important for membrane fusion.

Bousse T, Takimoto T, Gorman WL, Takahashi T, Portner A.

Virology. 1994 Nov 1;204(2):506-14.

PMID:
7941317
50.

Virus-specific CD8+ T-cell memory determined by clonal burst size.

Hou S, Hyland L, Ryan KW, Portner A, Doherty PC.

Nature. 1994 Jun 23;369(6482):652-4.

PMID:
7516039

Supplemental Content

Loading ...
Support Center